We are live on ! Find out more
CRBU icon

Caribou Biosciences

151 hedge funds and large institutions have $343M invested in Caribou Biosciences in 2024 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 44 increasing their positions, 46 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 20

13% more call options, than puts

Call options by funds: $628K | Put options by funds: $555K

5% more funds holding

Funds holding: 144151 (+7)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

4% less repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 46

5.46% less ownership

Funds ownership: 79.37%73.91% (-5.5%)

15% less capital invested

Capital invested by funds: $402M → $343M (-$59.2M)

Holders
151
Holders Change
+7
Holders Change %
+4.86%
% of All Funds
2.18%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
27
Increased
44
Reduced
46
Closed
20
Calls
$628K
Puts
$555K
Net Calls
+$73K
Net Calls Change
-$152K
Name Holding Trade Value Shares
Change
Change in
Stake
Mitsubishi UFJ Asset Management
76
Mitsubishi UFJ Asset Management
Japan
$217K -$11.9K -1,936 -4%
MIM
77
MetLife Investment Management
New Jersey
$209K
AIG
78
American International Group
New York
$207K -$2.13K -346 -0.9%
Royal Bank of Canada
79
Royal Bank of Canada
Ontario, Canada
$199K -$1.5M -243,180 -86%
Ameriprise
80
Ameriprise
Minnesota
$188K +$25 +4 +0%
CIC
81
Cornercap Investment Counsel
Georgia
$184K +$220K +35,754 New
Deutsche Bank
82
Deutsche Bank
Germany
$183K +$4.84K +785 +2%
Wells Fargo
83
Wells Fargo
California
$181K +$51.6K +8,374 +31%
New York State Common Retirement Fund
84
New York State Common Retirement Fund
New York
$176K -$105 -17 -0%
TWM
85
Thrive Wealth Management
Pennsylvania
$164K
Manulife (Manufacturers Life Insurance)
86
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$161K -$5.29K -858 -3%
SPS
87
Susquehanna Portfolio Strategies
Pennsylvania
$158K
Walleye Trading
88
Walleye Trading
New York
$155K +$185K +30,071 New
Tudor Investment Corp
89
Tudor Investment Corp
Connecticut
$152K +$182K +29,583 New
BCM
90
Bayesian Capital Management
New York
$151K +$181K +29,284 New
VOYA Investment Management
91
VOYA Investment Management
Georgia
$139K -$34.7K -5,632 -17%
SG Americas Securities
92
SG Americas Securities
New York
$137K -$79.8K -12,942 -33%
Assenagon Asset Management
93
Assenagon Asset Management
Luxembourg
$137K -$13.8M -2,231,947 -99%
EFM
94
E Fund Management
China
$132K +$32.3K +5,235 +26%
LPL Financial
95
LPL Financial
California
$123K +$147K +23,897 New
T. Rowe Price Associates
96
T. Rowe Price Associates
Maryland
$121K +$15.7K +2,545 +12%
ET
97
Entropy Technologies
New York
$113K +$136K +22,062 New
Principal Financial Group
98
Principal Financial Group
Iowa
$113K -$10.6K -1,726 -7%
PFCS
99
Pale Fire Capital SE
Czech Republic
$112K -$40.1K -6,500 -23%
ProShare Advisors
100
ProShare Advisors
Maryland
$107K +$10.5K +1,704 +9%

CRBU Hedge Fund Activity: Q1 2024 in Review

151 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Caribou Biosciences (CRBU) for Q1 2024, worth a combined $343M — down 15% from $402M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new CRBU positions and 20 closed out — a net gain of 7 holders — while 44 added to existing stakes and 46 trimmed.

The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $11.4M. The largest seller was Assenagon Asset Management, cutting an estimated $13.8M.

  • 151 institutional investors held Caribou Biosciences (CRBU) as of Q1 2024, up from 144 in Q4 2023.
  • Funds reported $343M of Caribou Biosciences stock for Q1 2024, down 15% quarter-over-quarter.
  • 27 funds opened new Caribou Biosciences positions in Q1 2024 and 20 closed out, a net change of +7 holders.
  • The largest Caribou Biosciences buyer in Q1 2024 was Schonfeld Strategic Advisors, an estimated $11.4M added.
  • The largest Caribou Biosciences seller in Q1 2024 was Assenagon Asset Management, an estimated $13.8M sold.

Based on aggregated 13F filings for Q1 2024.